Skip to content

Water Content in E-Liquids

Water Content In E-Liquids

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05257109
Enrollment
31
Registered
2022-02-25
Start date
2022-08-01
Completion date
2023-03-10
Last updated
2024-10-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Nicotine E-Cigarette Use

Brief summary

This study looks at the effect of manipulating the water concentration of certain e-liquids on sensory perception.

Detailed description

This study looks at the effect of manipulating water concentration on e-cigarettes that contain aldehyde flavor chemicals on sensory perception. Regular e-cigarette users will be asked to complete 2 lab sessions in which they will sample 4 nicotine containing e-liquids. Each e-liquid will be sampled in four water concentration manipulations. Researchers will examine influence of flavor and water concentrations on sensory experience including appeal/liking and irritation and harshness.

Interventions

OTHERWater Concentration 1

E-liquid containing 36mg/ml pronated nicotine will be administered with no alteration to water concentration.

OTHERWater Concentration 2

E-liquid containing 36mg/ml pronated nicotine will be administered with 5% total water concentration of e-liquid.

OTHERWater Concentration 3

E-liquid containing 36mg/ml pronated nicotine will be administered with 10% total water concentration of e-liquid.

OTHERWater Concentration 4

E-liquid containing 36mg/ml pronated nicotine will be administered with 20% total water concentration of e-liquid.

Sponsors

National Institute on Drug Abuse (NIDA)
CollaboratorNIH
Yale University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
OTHER
Masking
DOUBLE (Subject, Investigator)

Masking description

Double blind, both participant and investigator will be blind to e-liquid being administered

Intervention model description

Within subject design, all participants will receive all e-liquid flavors/water concentrations

Eligibility

Sex/Gender
ALL
Age
21 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

* at least 21 years old * able to read/write * \>/= 6 mths e-cig use * regular e-cig use (\>/= 4 days/week) * use of flavored e-cigs * use of nicotine containing e-cigs * urine cotinine \>/= 200ng/ml * no plan to quit e-cig use

Exclusion criteria

* breastfeeding, pregnant, trying to become pregnant * Medical conditions that increase risk of respiratory problems among participants * Current use of illegal substances * Medical conditions increasing risk of respiratory problems in nonpatient populations * Current diagnosis of an untreated psychiatric condition * Not fully vaccinated for Coronavirus-19

Design outcomes

Primary

MeasureTime frameDescription
Irritation/Harshnessimmediately after intervention, up to 15 minutesChange in irritation at each water level as measured by the computerized Generalized Labeled Magnitude Scale (gLMS). Participants will self-report their responses using a computer mouse to indicate where on the scale response falls. The Generalized Labeled Magnitude Scales (gLMS) are category ratio scales with seven semantic labels: no sensation, barely detectable, weak, moderate, strong, very strong, and strongest imaginable, positioned quasi-logarithmically as per empirically determined semantic magnitudes on a 0-100 scale (strongest imaginable at the 100 end).
Appeal Assessed Using the Labeled Hedonic Scale (LHS) Ranging From -100 to 100immediately after intervention, up to 15 minutesChange in appeal at each water level as measured by the computerized Labeled Hedonic Scale (LHS). Participants will self-report their responses using a computer mouse to indicate where on the scale response falls. The Labeled Hedonic Scale (LHS) is a bipolar category ratio scale that ranges from -100 (most disliked, minimum score) to 100 (most liked, maximum score), with 'neither liked nor disliked' as midpoint (0). Scores range from -100 (minimum) to 100 (maximum). Negative scores indicate dislike (lack of appeal) and positive scores indicate liking (appeal).
Appeal Assessed Using the Drug Effects Questionnaire (DEQ)immediately after intervention, up to 15 minutesChange in appeal at each water level as measured by the computerized version of the Drug Effects Questionnaire (DEQ). Participants will self-report their responses using a computer mouse to indicate where on the scale response falls. A modified version of the Drug Effects Questionnaire (DEQ) will be used in which participants rate acute responses to the e-cigarette on a 0-100mm scale from not at all (0mm) to extremely (100mm).

Countries

United States

Participant flow

Recruitment details

108 people were phone screened for eligibility. 54 attended an in person intake appointment. Of those, 31 met inclusion criteria and were enrolled in the study and 30 participants complete all study procedures.

Pre-assignment details

31 of 54 intakes were randomized to receive study procedures. 22 people did not meet inclusion criteria at the time of intake and were not enrolled and 1 person was not available at the time of the lab sessions to participate.

Participants by arm

ArmCount
Experimental Order A-D (All Participants Received All Conditions, Order Was Randomized)
All participants received all conditions, order was randomized
31
Total31

Withdrawals & dropouts

PeriodReasonFG000FG001FG002FG003
Overall StudyWithdrawal by Subject1000

Baseline characteristics

CharacteristicExperimental Order A-D (All Participants Received All Conditions, Order Was Randomized)
Age, Categorical
<=18 years
0 Participants
Age, Categorical
>=65 years
0 Participants
Age, Categorical
Between 18 and 65 years
31 Participants
Age, Continuous35.3 years
STANDARD_DEVIATION 10.4
Ethnicity (NIH/OMB)
Hispanic or Latino
11 Participants
Ethnicity (NIH/OMB)
Not Hispanic or Latino
20 Participants
Ethnicity (NIH/OMB)
Unknown or Not Reported
0 Participants
Race (NIH/OMB)
American Indian or Alaska Native
2 Participants
Race (NIH/OMB)
Asian
5 Participants
Race (NIH/OMB)
Black or African American
2 Participants
Race (NIH/OMB)
More than one race
3 Participants
Race (NIH/OMB)
Native Hawaiian or Other Pacific Islander
1 Participants
Race (NIH/OMB)
Unknown or Not Reported
0 Participants
Race (NIH/OMB)
White
18 Participants
Region of Enrollment
United States
31 participants
Sex: Female, Male
Female
16 Participants
Sex: Female, Male
Male
15 Participants

Adverse events

Event typeEG000
affected / at risk
EG001
affected / at risk
EG002
affected / at risk
EG003
affected / at risk
deaths
Total, all-cause mortality
0 / 100 / 80 / 60 / 7
other
Total, other adverse events
0 / 100 / 80 / 60 / 7
serious
Total, serious adverse events
0 / 100 / 80 / 60 / 7

Outcome results

Primary

Appeal Assessed Using the Drug Effects Questionnaire (DEQ)

Change in appeal at each water level as measured by the computerized version of the Drug Effects Questionnaire (DEQ). Participants will self-report their responses using a computer mouse to indicate where on the scale response falls. A modified version of the Drug Effects Questionnaire (DEQ) will be used in which participants rate acute responses to the e-cigarette on a 0-100mm scale from not at all (0mm) to extremely (100mm).

Time frame: immediately after intervention, up to 15 minutes

ArmMeasureValue (MEAN)Dispersion
No Water AddedAppeal Assessed Using the Drug Effects Questionnaire (DEQ)48.99 score on a scaleStandard Error 3.71
5% Water AddedAppeal Assessed Using the Drug Effects Questionnaire (DEQ)47.94 score on a scaleStandard Error 3.71
10% Water AddedAppeal Assessed Using the Drug Effects Questionnaire (DEQ)45.94 score on a scaleStandard Error 3.71
20% Water AddedAppeal Assessed Using the Drug Effects Questionnaire (DEQ)42.97 score on a scaleStandard Error 3.72
p-value: <0.05Mixed Models Analysis
Primary

Appeal Assessed Using the Labeled Hedonic Scale (LHS) Ranging From -100 to 100

Change in appeal at each water level as measured by the computerized Labeled Hedonic Scale (LHS). Participants will self-report their responses using a computer mouse to indicate where on the scale response falls. The Labeled Hedonic Scale (LHS) is a bipolar category ratio scale that ranges from -100 (most disliked, minimum score) to 100 (most liked, maximum score), with 'neither liked nor disliked' as midpoint (0). Scores range from -100 (minimum) to 100 (maximum). Negative scores indicate dislike (lack of appeal) and positive scores indicate liking (appeal).

Time frame: immediately after intervention, up to 15 minutes

ArmMeasureValue (MEAN)Dispersion
No Water AddedAppeal Assessed Using the Labeled Hedonic Scale (LHS) Ranging From -100 to 1009.91 score on a scale (-100 to 100)Standard Deviation 3.78
5% Water AddedAppeal Assessed Using the Labeled Hedonic Scale (LHS) Ranging From -100 to 10010.41 score on a scale (-100 to 100)Standard Deviation 3.79
10% Water AddedAppeal Assessed Using the Labeled Hedonic Scale (LHS) Ranging From -100 to 1007.1 score on a scale (-100 to 100)Standard Deviation 3.79
20% Water AddedAppeal Assessed Using the Labeled Hedonic Scale (LHS) Ranging From -100 to 1003.87 score on a scale (-100 to 100)Standard Deviation 3.79
p-value: <0.05Mixed Models Analysis
Primary

Irritation/Harshness

Change in irritation at each water level as measured by the computerized Generalized Labeled Magnitude Scale (gLMS). Participants will self-report their responses using a computer mouse to indicate where on the scale response falls. The Generalized Labeled Magnitude Scales (gLMS) are category ratio scales with seven semantic labels: no sensation, barely detectable, weak, moderate, strong, very strong, and strongest imaginable, positioned quasi-logarithmically as per empirically determined semantic magnitudes on a 0-100 scale (strongest imaginable at the 100 end).

Time frame: immediately after intervention, up to 15 minutes

ArmMeasureValue (MEAN)Dispersion
No Water AddedIrritation/Harshness1.04 units on a scaleStandard Deviation 0.05
5% Water AddedIrritation/Harshness1.07 units on a scaleStandard Deviation 0.05
10% Water AddedIrritation/Harshness1.03 units on a scaleStandard Deviation 0.05
20% Water AddedIrritation/Harshness1.01 units on a scaleStandard Deviation 0.05
p-value: 0.0014Mixed Models Analysis

Source: ClinicalTrials.gov · Data processed: May 22, 2026